BI 2536

Catalog No.S1109

BI 2536 Chemical Structure

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Size Price Stock Quantity  
In DMSO USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
USD 997 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 55 Publications

13 Customer Reviews

  • (C) HeLa cells were treated with inhibitors of Aurora B (hesperadin), Aurora A (Aurora A inhibitor I), CDK1 (roscovitine), or PLK1 (BI2536) for 2 hours before immunostaining for tubulin and phosphorylated RV[S/T]F (p-RV[S/T]F). Nuclei are indicated with DAPI. Control cells were not treated with any inhibitor. More than 50 cells were imaged for each condition in three independent experiments. Scale bar, 20 μm.

    Science, 2018, 11(530), doi: 10.1126/scisignal.aai8669. BI 2536 purchased from Selleck.

    Comparison between Genetic Ablation of Cdc20 and Current Mitotic Drugs (C) Transformed Cdc20(lox/lox); RERT(+/Cre) MEFs were subcutaneously injected into the two flanks of SCID mice, and tumors were scored every 2-3 days.These mice were injected i.p. (three injections per week) with 4-OHT or mitotic drugs (taxol, vincristine, and BI2536) when tumors reached about 200 mm3 of volume (day 11; arrow) (n = 8 mice per group). (D) Representative images of these fibrosarcomas 3 days after injection with 4-OHT (to generate Cdc20(D/D) cells), BI2536, or taxol. These mice were injected with 10 μM BrdU to score DNA replication. CA3, immunodetection of active caspase 3. Scale bars, 50 or 10 μM (insets).

    Cancer Cell 2010 18, 641–654. BI 2536 purchased from Selleck.

  • (a,b) RPE1 cells transfected with control or either of two B56-PP2A siRNA pools (1, 2) were incubated in MG132 (10µM, 15 min), followed by the addition of BI2536 (40 nM) or DMSO for 45 min. (a) The frequency of mitotic cells with few or absent cold-stable K-bres . (b) Maximum-intensity projection of tubulin (green) and an overlay with kinetochores (CREST, red) in B56-PP2A-siRNA (pool 2) cells treated with DMSO or BI2536 (40 nM). Insets are 3 enlargement of the optical sections spanning the outlined centromeres.

    Nat Cell Biol 2011 13, 1265-71. BI 2536 purchased from Selleck.

    (a) HeLa Tet-On cells were treated with the indicated siRNAs, arrested in mitosis using 500 nM nocodazole (Noc) and 10 μM MG132, and then treated with or without BI 2536. The endogenous Cdc20 was immunoprecipitated from these cells and blotted with the indicated antibodies. The mitotic index of each sample is indicated below each lane. The bottom graph shows the quantification of the Cdc20-pS92 signal normalized to the total Cdc20 signal (mean±range; n=2 independent experiments).

    Nat Commun, 2016, 7:10818. BI 2536 purchased from Selleck.

  • Treatment with BI 2536 induces cell-cycle arrest in NB TICs and aberrant accumulation of cyclin B1 and p21. C, expression of cyclin B1 and p21 was assessed in NB88R2 following 16 and 24-hour treatment with different doses of BI 2536 (10, 30, and 100 nmol/L). ERK1 (extracellular signal regulated kinase 1) was used as the loading control. D, inhibition of PLK1 was assessed by in vitro kinase assay following treatment of NB88R2 for 3 hours with BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    Treatment with BI 2536 induces cell death via apoptosis. A,treatment with BI 2536 (10, 30, and 100 nmol/L) reduces viable cell numbers as assessed by trypan blue exclusion. B, representative Western blot demonstrating accumulation of cleaved PARP following treatment with 10 nmol/L BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • BI 2536 inhibits NB tumor growth in vivo. A and B, NOD/SCID mice bearing 50- to100-mm3 tumors were injected intravenously with either vehicle (0.1N HCl per saline) or 12.5 to 25 mg/kg BI 2536 for 2 consecutive days a week, for a total of 3 cycles.Two independent experiments were performed in each case with 5 animals per group. Representative tumor growth data are shown.

     

     

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    animals with 50- to 100-mm3 tumors were randomized into 4 groups: group 1 injected intravenously with vehicle (0.1N HCl per saline), group 2 injected intravenously with 12.5 mg/kg of BI 2536 (2 consecutive days, 3 cycles), group 3 injected i.p. with 10 mg/kg of irinotecan (3 doses total, 3 days apart), and group 4 injected with BI 2536 and irinotecan. Both representative tumor growth data and a Kaplan-Meyer survival plot are shown.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • Plk-1 knockdown and inhibition by BI 2536 and viability of human melanoma cell lines M14 and WM-115 as demonstrated by MTT assay. Experiments were performed in triplicate. One representative experiment is shown. *P<0.001, ANOVA test with Tukey’s post-test. ANOVA, analysis of variance; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Plk-1, polo-like kinase 1; siRNA, small-interfering RNA; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. BI 2536 purchased from Selleck.

    Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like cells after treatment with BI 2536 for 24 and 48 hours, respectively.

    Oncotarget, 2017, 8(23):37633-37645. BI 2536 purchased from Selleck.

  • Cells with decreased GRK5 expression are more sensitive to PLK1 inhibition.A , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h of treatment with 0-120 nM BI 2536 as determined by trypan blue exclusion (n = 6).B , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h treatment with 0 –120 nM GSK461364, as determined by trypan blue exclusion ( n = 4).

    J Biol Chem 2012 287(21), 17088-99. BI 2536 purchased from Selleck.

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

  • Example dose response curves of the PLK-1 inhibitor BI-2536. During the large dose response study for each reference compounds 8 dilutions were tested. Curves for IC50 determination for two independent experiments for the PLK1 inhibitor BI-2536 are displayed. This inhibitor is also used to achieve the LC values. IC50 has been determined with 7.48 +/- 0.09 log [M] and 6.75 +/- 0.21 log [M]. Correlating assay performance data are displayed in Suppl. Fig. 5. 

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.
Features The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.
Targets
PLK1 [1]
(Cell-free assay)		 PLK2 [1]
(Cell-free assay)		 PLK3 [1]
(Cell-free assay)
0.83 nM 3.5 nM 9.0 nM
In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. [1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PSN1 NIrpN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfCNZZnUUN3ME2wMlAxPzd4IN88US=> Mnf1V2FPT0WU
ACN M2Tjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT5OnpKSzVyPUCuNFA5PDNizszN NGPhc|VUSU6JRWK=
TE-8 NHrsfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS2UFJKSzVyPUCuNFA6PDFizszN NF;i[JZUSU6JRWK=
LC-2-ad NWK5bmxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\leGlEPTB;MD6wNVA6OyEQvF2= NV;KNHVOW0GQR1XS
ALL-PO M{DFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEGzJO69VQ>? NX;LNlhxW0GQR1XS
EW-16 M4\rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEGzN|Yh|ryP MoPmV2FPT0WU
KM12 NGnHUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT6O4ZKSzVyPUCuNFE{PDhizszN NGPYb2FUSU6JRWK=
GI-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEGzPFMh|ryP MYnTRW5ITVJ?
LS-411N MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i3N2lEPTB;MD6wNVQxPyEQvF2= NHLUZWNUSU6JRWK=
ES8 M2TzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDqfIxKSzVyPUCuNFE1QTRizszN M1jzTHNCVkeHUh?=
SNU-C2B NX6xWpRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\lZlVkUUN3ME2wMlAyPTJ4IN88US=> MYnTRW5ITVJ?
CESS M3m2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMEG2NFIh|ryP NVPQdnVZW0GQR1XS
697 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3lTWM2OD1yLkCxOlY5KM7:TR?= M4PYTnNCVkeHUh?=
NCI-H1963 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HEOGlEPTB;MD6wNVY4OyEQvF2= M3;MTXNCVkeHUh?=
IA-LM M4jMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojQTWM2OD1yLkCxOlg5KM7:TR?= MXnTRW5ITVJ?
SW954 NELIT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPDTWM2OD1yLkCxO|A2KM7:TR?= M{XHZnNCVkeHUh?=
RL95-2 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXlTWM2OD1yLkCxO|M5KM7:TR?= NYXCN2l5W0GQR1XS
LXF-289 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXKeHpoUUN3ME2wMlAyPzdizszN MYLTRW5ITVJ?
OCUB-M M4jTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ZcXZKSzVyPUCuNFE5OjZizszN MkLSV2FPT0WU
RKO NX;PW2RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfVU4ZKSzVyPUCuNFE6QDdizszN M{TkXnNCVkeHUh?=
LOUCY M3;ZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO1TWM2OD1yLkCyNFUh|ryP NIriSI9USU6JRWK=
NOS-1 M2DFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEKwPVMh|ryP NF;lTpVUSU6JRWK=
A4-Fuk M4XWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjhXWlvUUN3ME2wMlAzOjF6IN88US=> MYLTRW5ITVJ?
A388 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPwPXRKSzVyPUCuNFIzOjdizszN MVjTRW5ITVJ?
TE-9 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjOTWM2OD1yLkCyNlYyKM7:TR?= Mne2V2FPT0WU
KURAMOCHI M1rvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LPZWlEPTB;MD6wNlI5PSEQvF2= MkfhV2FPT0WU
KALS-1 NYjvR5B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjQWFNKSzVyPUCuNFI{OzhizszN NGDaOm5USU6JRWK=
HOP-62 Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLzTWM2OD1yLkCyOFIh|ryP NX3tTGZwW0GQR1XS
RPMI-8402 NFvFSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMEK1NFgh|ryP NGLrbWhUSU6JRWK=
TE-1 M1nWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf4TWM2OD1yLkCyOVEzKM7:TR?= NXvkW2lZW0GQR1XS
CCRF-CEM MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPDOlFKSzVyPUCuNFI2PDNizszN M4G5W3NCVkeHUh?=
HUTU-80 NHPMbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LuU2lEPTB;MD6wNlYzPCEQvF2= MVTTRW5ITVJ?
NCI-H1648 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTWTWM2OD1yLkCyOlQ4KM7:TR?= MlXJV2FPT0WU
HCE-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnmTWM2OD1yLkCyOlgzKM7:TR?= NFXTR2FUSU6JRWK=
ETK-1 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TjcGlEPTB;MD6wNlc{PiEQvF2= M1vzdXNCVkeHUh?=
TE-15 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGwTWM2OD1yLkCyO|M5KM7:TR?= M{TYPHNCVkeHUh?=
BE-13 NU\m[4ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEK3OEDPxE1? NUi1N2MzW0GQR1XS
KE-37 NVX6enhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X0[GlEPTB;MD6wNlc1OSEQvF2= MVzTRW5ITVJ?
NCI-H1355 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPhTWM2OD1yLkCyO|g{KM7:TR?= M{PHenNCVkeHUh?=
TE-11 NVLM[pZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjyTWM2OD1yLkCyPFA6KM7:TR?= MniwV2FPT0WU
BL-70 NFrhRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\ITWM2OD1yLkCyPFU4KM7:TR?= MlSwV2FPT0WU
ES6 M1XMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEK4PFEh|ryP M1nSPXNCVkeHUh?=
GT3TKB NEjFeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W1VWlEPTB;MD6wNlk2OyEQvF2= M{nubHNCVkeHUh?=
LB647-SCLC M162T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTETWM2OD1yLkCzNVk2KM7:TR?= NGXZT4RUSU6JRWK=
NB13 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPJTWM2OD1yLkCzN|E3KM7:TR?= NX3jbokyW0GQR1XS
ST486 NHG2XolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S0UGlEPTB;MD6wN|M{PyEQvF2= NFvQXYZUSU6JRWK=
NCI-H82 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LQfGlEPTB;MD6wN|M1OyEQvF2= MWnTRW5ITVJ?
NTERA-S-cl-D1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMEOzPVkh|ryP MlnwV2FPT0WU
ES4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3CTWM2OD1yLkCzOFY{KM7:TR?= NHLHb2hUSU6JRWK=
SK-NEP-1 NHHaSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnodZdKSzVyPUCuNFM1QTlizszN MnTUV2FPT0WU
Becker NWH4NG1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHmXFNTUUN3ME2wMlA{PTV3IN88US=> NEPOOnNUSU6JRWK=
A101D MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\hW5FKSzVyPUCuNFM4PDhizszN NVHkeVdQW0GQR1XS
SK-UT-1 NXf1bXVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEO3O|Qh|ryP M3nhVHNCVkeHUh?=
SW982 NELCU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHZ[W9HUUN3ME2wMlA{PzlizszN MVLTRW5ITVJ?
TE-10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TIPWlEPTB;MD6wOFA1PiEQvF2= MVnTRW5ITVJ?
OVCAR-4 M3r2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHQZplvUUN3ME2wMlA1ODV7IN88US=> M16zNnNCVkeHUh?=
KP-N-YS NGHGZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULBN2RbUUN3ME2wMlA1ODh3IN88US=> MW\TRW5ITVJ?
BL-41 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXmTWM2OD1yLkC0NVI2KM7:TR?= NIj6NIdUSU6JRWK=
MZ1-PC NXK1dphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS2S3FbUUN3ME2wMlA1OTJ5IN88US=> NHfDXY9USU6JRWK=
PF-382 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMESxPVgh|ryP NXHvWJJWW0GQR1XS
MOLT-13 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyxflFKSzVyPUCuNFQzOzhizszN M2PEZ3NCVkeHUh?=
HCC1599 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17tVmlEPTB;MD6wOFI2QCEQvF2= MV7TRW5ITVJ?
IST-MEL1 NIXJTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMES0OFIh|ryP M3PvVXNCVkeHUh?=
LU-139 M{LuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfDWG5KSzVyPUCuNFQ1PDJizszN MX\TRW5ITVJ?
MS-1 NVnI[FFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH2T5NKSzVyPUCuNFQ4ODFizszN M1PYdXNCVkeHUh?=
MFH-ino MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L5b2lEPTB;MD6wOVAxOyEQvF2= NGCxRZdUSU6JRWK=
IMR-5 NFvjXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HUZWlEPTB;MD6wOVAzOSEQvF2= NXnqSHJ4W0GQR1XS
TE-5 MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCyWWp3UUN3ME2wMlA2ODZ|IN88US=> NX\pfHh2W0GQR1XS
DJM-1 NGjMdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXqTWM2OD1yLkC1NVQzKM7:TR?= NEe2bWRUSU6JRWK=
NB17 M3jESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2KxWmlEPTB;MD6wOVIxPyEQvF2= M{POWnNCVkeHUh?=
KARPAS-45 NFW1UoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEWzOVgh|ryP MVLTRW5ITVJ?
TGBC1TKB M1vPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvveWo2UUN3ME2wMlA2PDB3IN88US=> MUjTRW5ITVJ?
ML-2 M{TiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfU[pByUUN3ME2wMlA2PDF2IN88US=> MlrCV2FPT0WU
no-10 M{fUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne5TWM2OD1yLkC1OFc1KM7:TR?= MYHTRW5ITVJ?
CTV-1 NEDj[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\DdJNkUUN3ME2wMlA2PTB{IN88US=> Mn;IV2FPT0WU
SJSA-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfyTWM2OD1yLkC1OVIh|ryP NVrzN4xTW0GQR1XS
HC-1 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMEW1PVch|ryP NEO1UVBUSU6JRWK=
TE-12 NVfPOWc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m2SWlEPTB;MD6wOVYyOyEQvF2= NHjycG5USU6JRWK=
KY821 NV[zb2cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jJVmlEPTB;MD6wOVY{OiEQvF2= MU\TRW5ITVJ?
TALL-1 NUm5WnZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;WTWM2OD1yLkC1O|A5KM7:TR?= NETwPFNUSU6JRWK=
DEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMEW3NFkh|ryP NEjYbJVUSU6JRWK=
TE-6 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q1bWlEPTB;MD6wOVczOiEQvF2= NXHxNHFMW0GQR1XS
SK-LMS-1 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OxVGlEPTB;MD6wOVgxPSEQvF2= Ml[1V2FPT0WU
EW-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnDcIpKSzVyPUCuNFU5OzdizszN NXu4eFR3W0GQR1XS
8-MG-BA NHjPRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\RWGdKSzVyPUCuNFU5PTFizszN M1nlXnNCVkeHUh?=
NALM-6 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrWVFJKSzVyPUCuNFU6PzNizszN NWnsXXpJW0GQR1XS
LB771-HNC M4O4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEW5O|kh|ryP NX3ldG9QW0GQR1XS
HT-144 NUW5SpJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\mOWlEPTB;MD6wOlE{KM7:TR?= MnrqV2FPT0WU
KM-H2 NYX1foZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjGTWM2OD1yLkC2NlIyKM7:TR?= Mo\6V2FPT0WU
SF268 M4m0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnSU|JKSzVyPUCuNFYzQDZizszN MU\TRW5ITVJ?
RS4-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwME[zNFQh|ryP NXTJbndEW0GQR1XS
MHH-PREB-1 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfaOGtXUUN3ME2wMlA3OzF7IN88US=> NFHzO|ZUSU6JRWK=
ATN-1 NFnHfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\vPYpQUUN3ME2wMlA3OzR3IN88US=> NIXGO|hUSU6JRWK=
BB30-HNC NG\HbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXpTmtKSzVyPUCuNFY1OzZizszN M3L0SHNCVkeHUh?=
CPC-N MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWeyem1JUUN3ME2wMlA3PTJ2IN88US=> NFztd5JUSU6JRWK=
NB1 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TBS2lEPTB;MD6wOlYyOyEQvF2= NVPxfZVLW0GQR1XS
KS-1 NWnDWIN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPUTWM2OD1yLkC2O|Q5KM7:TR?= MonFV2FPT0WU
RXF393 NIXv[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TEW2lEPTB;MD6wOlc3PCEQvF2= M2nPWnNCVkeHUh?=
IST-SL2 NEXjcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHMSm9KSzVyPUCuNFcxODRizszN NWn3UG5mW0GQR1XS
GI-ME-N M{nUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnxVW9RUUN3ME2wMlA4Ojh4IN88US=> M3vTPXNCVkeHUh?=
VA-ES-BJ MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3LeVVKSzVyPUCuNFc1PzVizszN MVTTRW5ITVJ?
NCI-H1581 M2G5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DlcWlEPTB;MD6wO|Q4QCEQvF2= Mn\jV2FPT0WU
U-266 M1y0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfCTWM2OD1yLkC3OFk4KM7:TR?= M135RnNCVkeHUh?=
DMS-114 MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEe1Nlgh|ryP NYjsPY1EW0GQR1XS
NCI-H187 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILvZ49KSzVyPUCuNFc4OjZizszN MY\TRW5ITVJ?
SW962 M3vpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX1TWM2OD1yLkC3PFM6KM7:TR?= MlfaV2FPT0WU
MONO-MAC-6 NV3VR4k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjHXnRoUUN3ME2wMlA4QTh4IN88US=> NUX3OoNoW0GQR1XS
MOLT-16 NFvLXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfMS3oyUUN3ME2wMlA5OTJzIN88US=> NUXNZlB6W0GQR1XS
KNS-42 M3L4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPBVJZyUUN3ME2wMlA5OTZzIN88US=> NXO2bIRTW0GQR1XS
CMK NHzmc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnKN5JRUUN3ME2wMlA5OjJ3IN88US=> M4TR[XNCVkeHUh?=
Ramos-2G6-4C10 M3vT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX5XXRKSzVyPUCuNFgzOjVizszN MWrTRW5ITVJ?
Daudi MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrwTWM2OD1yLkC4NlU3KM7:TR?= NVXPU2ZRW0GQR1XS
NCI-H510A Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEizN|Yh|ryP NXGyRXNRW0GQR1XS
LB831-BLC NF3UPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDFTWM2OD1yLkC4OVYyKM7:TR?= M2DsUHNCVkeHUh?=
HEL NXr3TZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEi2Olgh|ryP MWTTRW5ITVJ?
LU-134-A NULTRoxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH3UopKSzVyPUCuNFg4ODhizszN MUPTRW5ITVJ?
NCI-H1694 NEfIdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHSN2dFUUN3ME2wMlA5PzR2IN88US=> M13TdnNCVkeHUh?=
KGN MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEi3OVkh|ryP MYPTRW5ITVJ?
A253 NHXoe|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfDTWM2OD1yLkC4PFIzKM7:TR?= M2DiWXNCVkeHUh?=
DG-75 NXTQS4xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEi5NlIh|ryP M{jrNnNCVkeHUh?=
MOLT-4 NVjLbY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NViy[3BtUUN3ME2wMlA5QTh|IN88US=> MVvTRW5ITVJ?
NCI-SNU-5 NIrRR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vNOmlEPTB;MD6wPVI2QCEQvF2= Mn3kV2FPT0WU
ONS-76 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTNRW5jUUN3ME2wMlA6Ojd4IN88US=> NF3WOZpUSU6JRWK=
NCI-H446 M4\lZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEm0OlIh|ryP MmHQV2FPT0WU
COR-L279 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEm1OVYh|ryP NFXGTJFUSU6JRWK=
Calu-6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml70TWM2OD1yLkC5OVk5KM7:TR?= M4jrOXNCVkeHUh?=
BC-3 NIrsPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\QOYhKSzVyPUCuNFk3PjJizszN NV;W[WpxW0GQR1XS
NCI-H2126 NFTLcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrKZ5hKSzVyPUCuNFk4QTFizszN NWX5Z4pmW0GQR1XS
NCI-H1882 M2Gx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknMTWM2OD1yLkC5PFA6KM7:TR?= NUTLZYttW0GQR1XS
BB65-RCC M3jRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMUCyPVQh|ryP NHvJc3FUSU6JRWK=
DU-4475 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3PeYlKSzVyPUCuNVA1ODdizszN NYfIVGNUW0GQR1XS
NCI-H526 MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDFS5BKSzVyPUCuNVA1PCEQvF2= NUS1SHZyW0GQR1XS
NEC8 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X3PGlEPTB;MD6xNFUzPSEQvF2= M{XyZ3NCVkeHUh?=
NCI-H1304 NWDwV2pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMUC1PVQh|ryP NX7tbHltW0GQR1XS
L-540 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmz[IZNUUN3ME2wMlExPzB6IN88US=> M4nzZXNCVkeHUh?=
NCI-SNU-16 M1zzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrRSppKSzVyPUCuNVA4PDJizszN NF3PPFhUSU6JRWK=
HD-MY-Z NV72WpZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMUC4OVYh|ryP MVfTRW5ITVJ?
K-562 NIHpSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSzNGpEUUN3ME2wMlExQDV6IN88US=> MXrTRW5ITVJ?
JAR M3Hlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMUC5NlUh|ryP NHOwWpRUSU6JRWK=
MZ2-MEL NFXJdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\ZTWM2OD1yLkGxNFUh|ryP MXrTRW5ITVJ?
L-363 NUL1WWdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nzfmlEPTB;MD6xNVA4QSEQvF2= MofnV2FPT0WU
BV-173 NVr4UIdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMUGyOFMh|ryP NF7tPYJUSU6JRWK=
NCI-H524 M4C4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\McWVKSzVyPUCuNVEzPzRizszN MmfzV2FPT0WU
EoL-1-cell M{e4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPXUWVZUUN3ME2wMlEyPjd{IN88US=> MVLTRW5ITVJ?
K052 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm0XGo3UUN3ME2wMlEyPzF{IN88US=> MWPTRW5ITVJ?
TK10 M{XuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMUG3Nlgh|ryP M4m1bHNCVkeHUh?=
KU812 NFfheGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X3cGlEPTB;MD6xNlA1PCEQvF2= MofBV2FPT0WU
RPMI-8226 NU\w[FZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D1XWlEPTB;MD6xNlA2OiEQvF2= NUju[3liW0GQR1XS
MZ7-mel NH:5c4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLjTWM2OD1yLkGyNlM4KM7:TR?= NW\sdIlwW0GQR1XS
SK-PN-DW NITXSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMUKyPFch|ryP NVTyfY5JW0GQR1XS
SR Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTCTWM2OD1yLkGyOFQyKM7:TR?= M4PXXHNCVkeHUh?=
RPMI-6666 NGq4eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD3TWM2OD1yLkGyO|Q{KM7:TR?= MWDTRW5ITVJ?
no-11 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMUK4Olkh|ryP M{X2ZnNCVkeHUh?=
EW-3 NIDI[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H2fmlEPTB;MD6xNlg6OyEQvF2= MmTZV2FPT0WU
LAMA-84 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XrVGlEPTB;MD6xN|E5PyEQvF2= MULTRW5ITVJ?
HT MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Hkd2lEPTB;MD6xN|U4PCEQvF2= Mlf3V2FPT0WU
KP-N-RT-BM-1 M1nYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTSTWM2OD1yLkGzOlEzKM7:TR?= NVPiWIZsW0GQR1XS
NCI-H747 M3r2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkOyTWM2OD1yLkGzO{DPxE1? NFvlOZFUSU6JRWK=
NCCIT NIj6eXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jxXmlEPTB;MD6xN|k{QSEQvF2= NF;RNWhUSU6JRWK=
MLMA MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXZT5hLUUN3ME2wMlE1OTZ5IN88US=> NHe0SW9USU6JRWK=
LP-1 NV;vT21GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonUTWM2OD1yLkG0NlQh|ryP M2G3bHNCVkeHUh?=
CAL-148 NVfP[HZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i3RmlEPTB;MD6xOFQ5OyEQvF2= Mn7LV2FPT0WU
GB-1 M1PhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LL[2lEPTB;MD6xOFUzPiEQvF2= MlPyV2FPT0WU
COR-L88 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TJR2lEPTB;MD6xOFgxOiEQvF2= NH3teVNUSU6JRWK=
NKM-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXzTWM2OD1yLkG0PVA3KM7:TR?= MnnsV2FPT0WU
NB5 M{TLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHzbJhKSzVyPUCuNVU1PjJizszN MV7TRW5ITVJ?
SH-4 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMUW0OlYh|ryP MlvDV2FPT0WU
EM-2 NF7tO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rHSWlEPTB;MD6xOVQ3PyEQvF2= MnX6V2FPT0WU
TGBC24TKB M3Hodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDtO41KSzVyPUCuNVU3PTlizszN M4roXnNCVkeHUh?=
SCLC-21H MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnWS2FKSzVyPUCuNVU4ODJizszN M1y1VXNCVkeHUh?=
COLO-684 NWTZVVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfvZWJWUUN3ME2wMlE2PzJzIN88US=> MXzTRW5ITVJ?
KINGS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XxUmlEPTB;MD6xOVkyKM7:TR?= MX7TRW5ITVJ?
LS-123 NWDwOWZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PBTGlEPTB;MD6xOVkyPyEQvF2= NIH2cmpUSU6JRWK=
MC116 M2HrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DHWWlEPTB;MD6xOlE2QCEQvF2= MVfTRW5ITVJ?
SU-DHL-1 MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMU[yNFYh|ryP NGLxPZNUSU6JRWK=
NCI-H64 NH\sUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPBRVhOUUN3ME2wMlE3OzR5IN88US=> MmqyV2FPT0WU
HCE-T Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMU[1NFQh|ryP MWDTRW5ITVJ?
LOXIMVI M4fadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMU[5OFkh|ryP Mlf0V2FPT0WU
ARH-77 NVnjeYUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;sTWlEPTB;MD6xO|M4QSEQvF2= NHHjWJlUSU6JRWK=
DOHH-2 NUHvdVh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTMTWM2OD1yLkG3OlczKM7:TR?= MX;TRW5ITVJ?
COLO-320-HSR NIfYR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\NTWM2OD1yLkG4NVU1KM7:TR?= Mnr2V2FPT0WU
NB6 NXvzV4hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjnTFNIUUN3ME2wMlE5PTZ4IN88US=> MYLTRW5ITVJ?
L-428 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTObVVyUUN3ME2wMlE5QDF|IN88US=> NV\oNIRMW0GQR1XS
SNB75 NEHxPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\rTWM2OD1yLkG4PFI1KM7:TR?= M1v0[3NCVkeHUh?=
NCI-H2141 M3LVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjE[5JkUUN3ME2wMlE6ODFzIN88US=> MmfoV2FPT0WU
KARPAS-299 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPuTWM2OD1yLkG5NlQyKM7:TR?= MYHTRW5ITVJ?
LC4-1 MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMUm1NFIh|ryP MoTiV2FPT0WU
UACC-257 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT6b283UUN3ME2wMlE6QTR5IN88US=> NV3aTYxqW0GQR1XS
EVSA-T NGXndXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O2XmlEPTB;MD6yNFMyOiEQvF2= NGjnT|VUSU6JRWK=
JiyoyeP-2003 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPwVWxKSzVyPUCuNlA1PzdizszN MYnTRW5ITVJ?
NCI-H720 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTmT2pKSzVyPUCuNlA2OjVizszN M2TpOHNCVkeHUh?=
GAK NETsbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\DO3IyUUN3ME2wMlIyOTh7IN88US=> NWG2T5BxW0GQR1XS
HH MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;VXZVKSzVyPUCuNlE1ODVizszN M3j1S3NCVkeHUh?=
NCI-H1436 Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnFUlBKSzVyPUCuNlE1PjRizszN MVLTRW5ITVJ?
GR-ST MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi1TWM2OD1yLkKxOFg5KM7:TR?= NULqfYZqW0GQR1XS
BC-1 M1r6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWxVYJKSzVyPUCuNlI3OTZizszN NFyxVmFUSU6JRWK=
SIG-M5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfrd2RKSzVyPUCuNlI4OjdizszN NV7uNIJkW0GQR1XS
NCI-H345 NWHmVoFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMkO4NFUh|ryP MoixV2FPT0WU
OPM-2 M4qwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLMc|FUUUN3ME2wMlI{QDh{IN88US=> MWrTRW5ITVJ?
LB1047-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrnTWM2OD1yLkK0OFEh|ryP NXLrdYx6W0GQR1XS
CTB-1 NVXOV3FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLsWpBDUUN3ME2wMlI1PDl|IN88US=> MUHTRW5ITVJ?
A3-KAW NYDjOFZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fYVmlEPTB;MD6yOVM1OSEQvF2= M3rUR3NCVkeHUh?=
SF126 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m2emlEPTB;MD6yOVM5OyEQvF2= NV3RXGxzW0GQR1XS
KARPAS-422 NG\KcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne5TWM2OD1yLkK1OFM2KM7:TR?= MWrTRW5ITVJ?
MEG-01 NELhXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXkcmlKSzVyPUCuNlU3PzNizszN M2ftcXNCVkeHUh?=
NCI-H209 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;YRVlKSzVyPUCuNlY{PzRizszN MUDTRW5ITVJ?
SBC-1 NETPZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHrTWM2OD1yLkK2OUDPxE1? NVHVcXV4W0GQR1XS
K5 NXn2boF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMk[5PFQh|ryP NITDdnRUSU6JRWK=
QIMR-WIL NEi0fW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMkexOVUh|ryP MWfTRW5ITVJ?
NMC-G1 NGXpOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWOxPZpLUUN3ME2wMlI5OjF5IN88US=> NUXTfIc{W0GQR1XS
IST-MES1 NYDBSnQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjaVG1KSzVyPUCuNlkzOzhizszN MXTTRW5ITVJ?
SW684 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7zTWVKSzVyPUCuN|AxPDdizszN NIfHTmRUSU6JRWK=
MV-4-11 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwM{C3PFgh|ryP M4DMTXNCVkeHUh?=
LAN-6 NF\wN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwM{G1O|Ih|ryP MXTTRW5ITVJ?
RH-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL1TWM2OD1yLkOxPFcyKM7:TR?= NY\hZ4hxW0GQR1XS
CP66-MEL Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXMeZR2UUN3ME2wMlMyQDd6IN88US=> M1[4NnNCVkeHUh?=
EC-GI-10 NU\tT2l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37me2lEPTB;MD6zNlk5PyEQvF2= MmGyV2FPT0WU
GDM-1 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwM{OwOVkh|ryP MXTTRW5ITVJ?
IST-SL1 NVXubWtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq2VnVKSzVyPUCuN|Q6OTRizszN MU\TRW5ITVJ?
KMOE-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXlTndbUUN3ME2wMlM2OTd3IN88US=> M3e2XXNCVkeHUh?=
OS-RC-2 NEPLVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nIeGlEPTB;MD6zOVU1PCEQvF2= NFjPdFZUSU6JRWK=
HDLM-2 NGPWZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfEVVdDUUN3ME2wMlM4QDF2IN88US=> NXHuV4lxW0GQR1XS
DSH1 NIruPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S4OGlEPTB;MD6zPFY{OSEQvF2= M1W3RnNCVkeHUh?=
LS-1034 MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37he2lEPTB;MD6zPFk2PCEQvF2= NYTiXXJ5W0GQR1XS
LB373-MEL-D M3XqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPaTWM2OD1yLkO5NVk4KM7:TR?= Mnr1V2FPT0WU
GOTO MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwNEKxNVgh|ryP MYrTRW5ITVJ?
MRK-nu-1 NX7PVmNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPSbmRKSzVyPUCuOFIzODVizszN NFPYfGJUSU6JRWK=
SK-MM-2 NVHkN|d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwNEO0OFIh|ryP MmPsV2FPT0WU
BOKU Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LtRWlEPTB;MD60N|c6OiEQvF2= NEfHWIdUSU6JRWK=
NOMO-1 M2PVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrGO3hKSzVyPUCuOFM5PiEQvF2= MYXTRW5ITVJ?
J-RT3-T3-5 NGT4[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwNES4O|gh|ryP M2fMS3NCVkeHUh?=
COLO-668 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwNEW2Olgh|ryP NFrlPZZUSU6JRWK=
SF539 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojSTWM2OD1yLkS4Olg1KM7:TR?= MojDV2FPT0WU
LB2518-MEL NYHuSZM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX1UVFsUUN3ME2wMlQ6PzB|IN88US=> M4XIXnNCVkeHUh?=
TE-441-T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G2OWlEPTB;MD61NFEzKM7:TR?= MUfTRW5ITVJ?
MDA-MB-134-VI NX7NXFFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LKR2lEPTB;MD61NFkzOSEQvF2= M{\pTXNCVkeHUh?=
SCC-3 NH;aOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HFeGlEPTB;MD61NVg4OyEQvF2= M3nZN3NCVkeHUh?=
KLE MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjMTIdKSzVyPUCuOVIyPzFizszN NV6wfJkyW0GQR1XS
LB2241-RCC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\OUYJKSzVyPUCuOVI2OjVizszN NHrTWGdUSU6JRWK=
NCI-H1417 MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPsRphSUUN3ME2wMlU{PDN3IN88US=> MlmyV2FPT0WU
NCI-H2081 M2PBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi2[YZKSzVyPUCuOVg3OTFizszN NF3kRXpUSU6JRWK=
NCI-H1522 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DNWmlEPTB;MD61PVM5OyEQvF2= MYHTRW5ITVJ?
NCI-H889 M{XiSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PvbWlEPTB;MD61PVg1PCEQvF2= MlvsV2FPT0WU
CGTH-W-1 NGrMT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNkC3OVUh|ryP M{WzSXNCVkeHUh?=
EB-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LEOWlEPTB;MD62NVE2OyEQvF2= M1fnXXNCVkeHUh?=
D-336MG NGnxdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LydWlEPTB;MD62NVc6OSEQvF2= NUnMd4Q4W0GQR1XS
LC-1F NVjxc5FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK4W4djUUN3ME2wMlYzPTl{IN88US=> MVvTRW5ITVJ?
MHH-NB-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTKTWM2OD1yLk[zPFAyKM7:TR?= NEX2UIFUSU6JRWK=
SK-N-FI NWC5NmVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorhTWM2OD1yLk[zPVEh|ryP MXrTRW5ITVJ?
NCI-H69 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi2TWdKSzVyPUCuOlQ5PzlizszN NWnUZ|V5W0GQR1XS
SCH MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILGTGxKSzVyPUCuOlYxOjNizszN NXTGSWZNW0GQR1XS
LS-513 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfjZnFKSzVyPUCuOlczPTlizszN M4PGXXNCVkeHUh?=
CP67-MEL NVLyUolIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvJUZdKSzVyPUCuOlc2QTZizszN MYPTRW5ITVJ?
GCIY MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDBPHZKSzVyPUCuO|A{PjNizszN NVjvSVRtW0GQR1XS
SHP-77 NHHxPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwN{C3N|Qh|ryP MoLWV2FPT0WU
EHEB NFzx[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XR[WlEPTB;MD63NVg2PCEQvF2= NX3rZ4g4W0GQR1XS
D-247MG NYXsUIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLRTI9JUUN3ME2wMlc{OjN{IN88US=> MVjTRW5ITVJ?
Raji NHf4eYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwN{S5PFkh|ryP MY\TRW5ITVJ?
MPP-89 NYHuN2pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwN{W5O|gh|ryP M2fCcnNCVkeHUh?=
EKVX NYH4fJFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXpWpVJUUN3ME2wMlc6ODd|IN88US=> NIjWV2tUSU6JRWK=
HCC2218 M1m1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXFTWM2OD1yLke5NVMyKM7:TR?= MlT2V2FPT0WU
KNS-81-FD NGLvVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\zVYdqUUN3ME2wMlgyODFzIN88US=> NHTGN|BUSU6JRWK=
HCC2157 M3XWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj5TWM2OD1yLki0PVUyKM7:TR?= M4TaUnNCVkeHUh?=
BT-474 NYnUUXdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO4TWM2OD1yLki4PFU1KM7:TR?= NH7ybFBUSU6JRWK=
NCI-H748 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzhTWM2OD1yLkmxNkDPxE1? NEm3fVdUSU6JRWK=
EW-24 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwOUKwNFIh|ryP NU\3ZnA1W0GQR1XS
D-263MG NFjQfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwOUS1NVIh|ryP M2T4RXNCVkeHUh?=
OMC-1 MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHZTWM2OD1yLkm2N|c{KM7:TR?= NGXDS4RUSU6JRWK=
NCI-H2196 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rzPWlEPTB;MD65O|c4PyEQvF2= NVm0eHBoW0GQR1XS
HAL-01 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwOUm4O|Ih|ryP MX\TRW5ITVJ?
NCI-H2107 NFvVT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwMEG4OVQh|ryP MWDTRW5ITVJ?
LB996-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHQTWM2OD1zLkC4NFUyKM7:TR?= M363ZnNCVkeHUh?=
NCI-H1395 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGxTWM2OD1zLkGwOlch|ryP M4TTb3NCVkeHUh?=
CHP-126 M4TYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uxOGlEPTB;MT6xOlE6QSEQvF2= MVLTRW5ITVJ?
NB69 NVviR2tVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vWNWlEPTB;MT6yOlE1QCEQvF2= Ml76V2FPT0WU
CAS-1 NIPzOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHlRZVKSzVyPUGuN|QzOzFizszN NWHBc3dCW0GQR1XS
JVM-3 M1TaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XTe2lEPTB;MT60O|g2PSEQvF2= NE\VNlVUSU6JRWK=
DMS-153 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwNUe2O|Qh|ryP MUnTRW5ITVJ?
SK-MEL-2 NH3kcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrLSVlKSzVyPUGuO|E4QDlizszN NYnYXYNWW0GQR1XS
NCI-H1155 NV22RXh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\wTWM2OD1zLkezOlc3KM7:TR?= M4PRNHNCVkeHUh?=
NCI-H1092 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwN{[xPFIh|ryP M4jIUnNCVkeHUh?=
LU-165 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjOe5U3UUN3ME2xMlg3PDd4IN88US=> NUPnOXFvW0GQR1XS
HL-60 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXqTWM2OD1zLkm5PVA5KM7:TR?= M3;qNHNCVkeHUh?=
REH NWroXWZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\m[GNKSzVyPUKuNFA2QDJizszN M1XP[HNCVkeHUh?=
JVM-2 MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJwME[xN|Uh|ryP NE\PW2FUSU6JRWK=
MN-60 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwMUezNFgh|ryP MmLDV2FPT0WU
SCC-15 NXSwcJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJwMkCyO{DPxE1? MkDmV2FPT0WU
SNU-C1 NGrEdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmraTWM2OD1{LkKxN|Q{KM7:TR?= M3vjeXNCVkeHUh?=
SK-MEL-1 NIr3bZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TiR2lEPTB;Mj6zNlA1PyEQvF2= NVvwU|l4W0GQR1XS
TGW NF31N|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H2SWlEPTB;Mj6zOVAzPyEQvF2= MVjTRW5ITVJ?
CA46 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm5dHZKSzVyPUKuO|U6PjdizszN NH3OdGZUSU6JRWK=
NCI-H23 NUDJd4lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJwOEC3PVEh|ryP NUXNb3ZbW0GQR1XS
MMAC-SF MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\pTI1KSzVyPUKuPFY3OjhizszN NWLyWJA1W0GQR1XS
NCI-H2171 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K3NGlEPTB;Mz6wN|Q1QCEQvF2= MoXOV2FPT0WU
A704 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxZmFKSzVyPUOuNVQyQTRizszN NVfmeJRCW0GQR1XS
DB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DKVWlEPTB;Mz6yOVU4PiEQvF2= NW\ie4I6W0GQR1XS
NCI-H719 NUj6WW12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwM{CzPFQh|ryP MYTTRW5ITVJ?
MC-CAR NG\mVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTNwNUS4NVch|ryP Ml\qV2FPT0WU
SIMA M{LnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TVfWlEPTB;Mz61PFQyPiEQvF2= NEC1bHJUSU6JRWK=
SW872 M2LiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPvXlF6UUN3ME2zMlc5OTBzIN88US=> NGKxcWpUSU6JRWK=
HCC1187 NV\GUnB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfQT5RKSzVyPUOuO|g{OTVizszN NHrP[GxUSU6JRWK=
EW-13 NX;sTZZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHqUYFKSzVyPUOuPFM1OTdizszN NF7wWHFUSU6JRWK=
NCI-SNU-1 NX;4NJk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRwMkG5PVkh|ryP MWDTRW5ITVJ?
NCI-H226 NWrYdlQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHEPHBKSzVyPUSuN|M3ODZizszN MXXTRW5ITVJ?
RPMI-8866 NFLy[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvETWM2OD12LkO2NFI6KM7:TR?= NI\CTW1USU6JRWK=
OCI-AML2 M3HYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPifopKSzVyPUSuOVUzOyEQvF2= MmTxV2FPT0WU
LU-65 NVfleXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTRwOUOwN|Mh|ryP MUnTRW5ITVJ?
SK-N-DZ M1;reGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PpZmlEPTB;NT62N|Q3PSEQvF2= NYHvSGMxW0GQR1XS
NB14 M3fVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPjW25[UUN3ME21Mlk4OTN3IN88US=> MmXvV2FPT0WU
COLO-829 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjl[3V[UUN3ME22MlM{OzV7IN88US=> NEfWU|lUSU6JRWK=
MHH-CALL-2 M3jMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSxbI83UUN3ME22MlUyPTB6IN88US=> MkDjV2FPT0WU
NCI-H1770 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1znTWlEPTB;Nj62OlkxPCEQvF2= NVnxUpFSW0GQR1XS
ECC4 NGe3RlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DmSWlEPTB;Nj64NlE4QSEQvF2= M2TwXHNCVkeHUh?=
A498 M3nJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzmUmE4UUN3ME22Mlg4OTl{IN88US=> MXrTRW5ITVJ?
DMS-79 M1HvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTdwMES1NVIh|ryP NVj1N2N4W0GQR1XS
P30-OHK M2PiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXB[oVTUUN3ME23MlIyQTB4IN88US=> M{ftenNCVkeHUh?=
D-502MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v3PWlEPTB;Nz65PFM3KM7:TR?= MWXTRW5ITVJ?
RCC10RGB NEDVOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7mTWM2OD16LkC2Nlgh|ryP NVTLTHJSW0GQR1XS
U-698-M NGf3dpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7nZo9KSzVyPUiuNlkzOjZizszN NIHxTlRUSU6JRWK=
BB49-HNC M{TN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3joSmlEPTB;OT60NlI3PSEQvF2= MVXTRW5ITVJ?
ES1 NWfxW5RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL2TWM2OD17Lk[4PVU3KM7:TR?= NXfOXoxlW0GQR1XS
MFM-223 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDaTWM2OD1zMD65PVI4KM7:TR?= MXLTRW5ITVJ?
C2BBe1 NH3ybJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFzLkO1NlMh|ryP MX;TRW5ITVJ?
EB2 M2XxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDqdlVKSzVyPUGyMlY5QDFizszN MWfTRW5ITVJ?
C8166 M{\Fcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Ty[2lEPTB;MUOuPFMxOyEQvF2= NGPQZ|ZUSU6JRWK=
ES3 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWyTWM2OD1zMz65PVc4KM7:TR?= M1uybHNCVkeHUh?=
NCI-H1650 NHHzW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS1fXNLUUN3ME2xOk4{PzZ3IN88US=> Ml;yV2FPT0WU
Mo-T MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3raRWlEPTB;MUeuOFAzQSEQvF2= NEK1SnJUSU6JRWK=
NB7 NWDWNXdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDtXoZiUUN3ME2xO{44PDZ5IN88US=> NFz0SnJUSU6JRWK=
ES7 M17EZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXTb25oUUN3ME2xPU42PTB5IN88US=> MYnTRW5ITVJ?
ES5 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXsTWM2OD1{MT63OlcyKM7:TR?= NXfGW5BxW0GQR1XS
MSTO-211H MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrrboRGUUN3ME2yNU45QDV6IN88US=> MV7TRW5ITVJ?
U-87-MG M3v1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ3LkG5OlYh|ryP NWPiTGdOW0GQR1XS
THP-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULmT5JMUUN3ME2yPU44OjBzIN88US=> NEX0NndUSU6JRWK=
NB10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3BTWM2OD1|MD6yOlk1KM7:TR?= M3nMdHNCVkeHUh?=
NH-12 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jPV2lEPTB;M{OuNlAyPyEQvF2= NX;WRo52W0GQR1XS
COLO-824 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[1UXBrUUN3ME2zOE4yODB4IN88US=> MnnmV2FPT0WU
SKM-1 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN5Lki0NlIh|ryP MWTTRW5ITVJ?
NCI-H1838 NXvFPHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSwb5A3UUN3ME2zPE4{Pzl5IN88US=> NF3ieppUSU6JRWK=
RL NEGyOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHGUpdKSzVyPUO5MlI1PzdizszN NETES5BUSU6JRWK=
COLO-800 NXnSNW0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETDV2JKSzVyPUSwMlA4PzNizszN NVrBOVQ{W0GQR1XS
KG-1 M17YWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;1TWM2OD12MD64PVU2KM7:TR?= NVrYO3ZiW0GQR1XS
TUR NIXWRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PoVWlEPTB;NEGuOlM6QSEQvF2= M3HaZXNCVkeHUh?=
LNCaP-Clone-FGC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfHWmJKSzVyPUSxMlkxOTdizszN NXnBRW1YW0GQR1XS
NCI-H322M NGe4eWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;4VGtZUUN3ME20Nk42QTh2IN88US=> MXTTRW5ITVJ?
LNCaP  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXCTWM2OD17MT6zJI5O Mn\5NlU2ODVzN{S=
C4-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK4Zoh{UUN3ME24JI5O M{SzVFI2PTB3MUe0
JURKAT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSyOEBp NIPOZ29KSzVyPUSxOk43PiCwTR?= MYGyOFUyQTl7NR?=
MOLT-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjUNlQhcA>? M4TQNGlEPTB;Mki1N{42KG6P NEP3eoozPDVzOUm5OS=>
REH MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGyNlQhcA>? M4G1OWlEPTB;Mki3MlY5KG6P M{Gzc|I1PTF7OUm1
NALM-6 NVjSV4JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSyOEBp Mmn4TWM2OD1|NEOzNEBvVQ>? MX:yOFUyQTl7NR?=
RS 4;11 NVrGT29qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPHZ28zPCCq M1PHbGlEPTB;NUG5MlA2KG6P MVOyOFUyQTl7NR?=
697 NELwbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyyOEBp MXTJR|UxRTJzMEeuNUBvVQ>? NF\jOVIzPDVzOUm5OS=>
SIL-ALL NX\Hd3RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:yS4RqOjRiaB?= M{\mbmlEPTB;MUm5Mlc4KG6P M{KxdVI1PTF7OUm1
CEM MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy1dZQzPCCq NUm0enRDUUN3ME21Nk4yQCCwTR?= MkTlNlQ2OTl7OUW=
P12 NYnrVFFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYiyOEBp NV\rRnlxUUN3ME2zPU4zPyCwTR?= NIXjc3gzPDVzOUm5OS=>
NALM-16 NEi5SIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTKNnZNOjRiaB?= MXnJR|UxRTl4LkK4JI5O MXmyOFUyQTl7NR?=
JURKAT NVH1foY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETNcpE1QCCq NGruRZJKSzVyPUG0Mlg1KG6P NFixVZIzPDVzOUm5OS=>
MOLT-4 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPFOFghcA>? NFTRPINKSzVyPUK2MlYhdk1? NX[3U|dPOjR3MUm5PVU>
REH NX[4T3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXvOFghcA>? MkX3TWM2OD12ND63NUBvVQ>? NEXkbHIzPDVzOUm5OS=>
NALM-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm0PEBp NUjnNpl6UUN3ME2yN{4zPiCwTR?= MUiyOFUyQTl7NR?=
RS 4;11 M3fZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq3VFY1QCCq NYPTPYRMUUN3ME2xOlQvOjhibl2= MXmyOFUyQTl7NR?=
697 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjaOFghcA>? MkTGTWM2OD1|MEWuN{BvVQ>? MnXJNlQ2OTl7OUW=
SIL-ALL MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr6ZpI1QCCq MUHJR|UxRTd2Lk[yJI5O NVGxWW82OjR3MUm5PVU>
CEM MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF74XnU1QCCq MlzvTWM2OD1{ND61OUBvVQ>? M2TZWlI1PTF7OUm1
P12 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvrOFghcA>? M{XyOWlEPTB;MUiuOFYhdk1? M4XxTFI1PTF7OUm1
NALM-16 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjqb4xnPDhiaB?= M4nTU2lEPTB;NkOuNlQhdk1? M1S2NlI1PTF7OUm1
JURKAT MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG3NkBp NXrPdo1HUUN3ME2zMlY2KG6P M1vIVVI1PTF7OUm1
MOLT-4 NITMRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\TO|IhcA>? MUfJR|UxRTdwM{mgcm0> NFnoUWszPDVzOUm5OS=>
REH NXf6Z4t4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D5dVczKGh? M3jKUWlEPTB;MU[uNFEhdk1? NVv1VIZQOjR3MUm5PVU>
NALM-6 MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn3RnNbPzJiaB?= NGDVNpVKSzVyPUGuO|ghdk1? MYGyOFUyQTl7NR?=
RS 4;11 M3Ll[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W3d|czKGh? MVfJR|UxRTRwM{igcm0> MlfyNlQ2OTl7OUW=
697 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DmSVczKGh? MkPLTWM2OD15ND6yPEBvVQ>? NFHGOIkzPDVzOUm5OS=>
SIL-ALL NXrPZYU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj4Z41wPzJiaB?= MXzJR|UxRTdwMjDuUS=> NV[3eW9POjR3MUm5PVU>
CEM NEX4b5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3NkBp NEHWXWJKSzVyPUWuOFIhdk1? Mke4NlQ2OTl7OUW=
P12 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\CUlczKGh? M3HS[2lEPTB;Nj6zO{BvVQ>? NGPVRpYzPDVzOUm5OS=>
NALM-16 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjNSWo4OiCq MVXJR|UxRTd5LkezJI5O M2LxPVI1PTF7OUm1
Y79 NVfTe4NvSXCxcITvd4l{KEG|c3H5 M2TQfFEuPTBibl2= NIj1fWEyOi9{NDDo NH\3dpNFVVOR NIrnXnhqdmS3Y3XkJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgTHQ> M2XmPFI1OzZ4Nk[1
WER-Rb-1 NYHEW2pVSXCxcITvd4l{KEG|c3H5 M3PiWFEuPTBibl2= M37XfFEzNzJ2IHi= MWPEUXNQ NIn0XVBqdmS3Y3XkJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgTHQ> NUiyflZwOjR|Nk[2OlU>
G7 NIfueGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HJ[WlEPTB;Mz6zJI5O NHzTT5czPDJyNEezNy=>
G166 NEfRTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr2[FVKSzVyPUeuNEBvVQ>? MXeyOFIxPDd|Mx?=
CB660 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPidlV5UUN3ME22MlQhdk1? NWnlc3lVOjR{MES3N|M>
CB1117 NYjM[ZhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln5TWM2OD1zNT62JI5O MWOyOFIxPDd|Mx?=
KB-3-1 NVWxVlgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwNEigxtEhOC53MzDuUS=> NXHZPYVtOjN7NkK0OFU>
KB-8-5-11 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPsU2lKSzVyPUWuNFEhyrFiMj6wNUBvVQ>? M4[1bVI{QTZ{NES1
KB-C-1 M1u3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX6y[olmUUN3ME2xOk44PiEEsTC0MlUyKG6P NH3zc40zOzl4MkS0OS=>
KB-V-1 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXiSVhKSzVyPUK4NU4zPCEEsTCzNU42PyCwTR?= NFj0fFkzOzl4MkS0OS=>
OVCAR-8 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnFTWM2OD15LkG5JOKyKDNwNkCgcm0> NVjNc4p3OjN7NkK0OFU>
NCI-ADR-RES NF73ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnlVo9KSzVyPUGyO|MvOzBiwsGgNVkyNjJyIH7N MV[yN|k3OjR2NR?=
MCF7 NF;Q[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\VXWlEPTB;NT6xNUDDuSBzLkS3JI5O M3v0RVI{QTZ{NES1
MCF7-FLV1000 NH3jTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i4VGlEPTB;M{mzMlE5KMLzIEe0Mlg{KG6P NWWzRYJzOjN7NkK0OFU>
S1 NEfsUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;qVlRiUUN3ME2yOE4{OCEEsTC0Mlc2KG6P NV[5VYg3OjN7NkK0OFU>
S1-M1-80 NVf1c49HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\lWoxKSzVyPUK2NU4xPiEEsTC0PE4zPSCwTR?= NX\iT5M1OjN7NkK0OFU>
CORL-23/P MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTRwM{igxtEhOS5{NTDuUS=> M{DHVFI{QTZ{NES1
CORL-23/R M{\GZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoraTWM2OD13LkG2JOKyKDFwOEOgcm0> MkHvNlM6PjJ2NEW=
NIH3T3 M{TqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfnUIxKSzVyPUSwMlYxKMLzIESuPVchdk1? MX:yN|k3OjR2NR?=
NIH3T3-G185 NH;HVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzDPIxGUUN3ME2yOFE{NjRyINMxJFQzOy54NjDuUS=> NF;vdXQzOzl4MkS0OS=>
pcDNA-HEK293 NVjEd4czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrGW41KSzVyPUKuO|UhyrFiMD62O{BvVQ>? M4DnblI{QTZ{NES1
MDR19-HEK293 M4D6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTh3LkWwJOKyKDF|Lk[3JI5O M2O5SVI{QTZ{NES1
R482-HEK293 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHae5ZlUUN3ME2yOU46PyEEsTC0Mlk2KG6P NXHVZWxuOjN7NkK0OFU>
MRP1-HEK293 M{jSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrLe|RvUUN3ME2yMlk6KMLzIEGuOFkhdk1? M1zLc|I{QTZ{NES1
SF188 NV65UVQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPxUJoyOC1zMECgcm0> MoPqNlQuQTZiaB?= M3[1VWROW09? M2XNPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36tJIRmeGWmZX70JI1idm6nch?= MWiyN|g5PzZ2NR?=
T98G NV3WXZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKxNE0yODBibl2= M{HES|I1NTl4IHi= MVHEUXNQ M4jHZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHPvcoNmdnS{YYTpc44uKGSncHXk[Y51KG2jbn7ldi=> NHq5NXAzOzh6N{[0OS=>
DU145 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M121eGROW09? M4HZc2lEPTEkiMy2NEBvVQ>? NV65cIlLOjN6OES0Nlg>
LNCaP  Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXCfopbTE2VTx?= NXL5dXpXUUN3MPMIwFc2KG6P NH\pN2ozOzh6NESyPC=>
PC3 NWL0blZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFiwVWFFVVOR MUjJR|Ux6oj:MUe1JI5O NIGwepozOzh6NESyPC=>
RT4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnhRVY6UUN3ME2yO{4zOSCwTR?= MWCyN|c6OjZ|OR?=
5637 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z2b2lEPTB;NEWuOFchdk1? M17yR|I{Pzl{NkO5
T24 NU[0eXU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnDTWM2OD15OT6xNkBvVQ>? NGHZRpQzOzd7Mk[zPS=>
MCF7  NID4UGlHfW6ldHnvckBCe3OjeR?= MlXKNVAxKG6P NXTybIFkOSCq NXr2VXVNTE2VTx?= M2PaXJJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZtMgS5Jm[jFuwrDT[4syNMLiUIOyMOKhW2W{cHnuZVMtKGGwZNMgW4l{eDJ? M{P4d|I{PzdyMkS0
KB-V1  MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\FN3FtUUN3ME2zMlkzKM7:TR?= NYjx[oN4OjN3OUOxPVY>
Hec50co MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXQcpNKSzVyPUWgcm0> M3PzOFI{OTR4Nki3
MDA-MB-468 M{m2WWFxd3C2b4Ppd{BCe3OjeR?= MV:xM|UwOTBibl2= M{\lO|I1NzR6L{eyJIg> NVTidVlETE2VTx?= NF;VN3pqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1Phb|I{OTR2Mkm0
MCF10A MUHBdI9xfG:|aYOgRZN{[Xl? NEj6VGEyNzVxMUCgcm0> M{P4NlI1NzR6L{eyJIg> M4fTPWROW09? MXrpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlHINlMyPDR{OUS=
Huh-7 NWnpepRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuxM|ExNzFyMD:xNFAxKG6P NYr0VWFCPDhiaB?= M2i1SYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh\G:|ZT3k[ZBmdmSnboTsfS=> NXT4V4VSOjJ5NEW1PFc>
Daoy  MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOxMlg4PS1{NECgcm0> MkPDO|IhcA>? MmXOSG1UVw>? MYTJR|UxRTVibl2= MoP4NlI{QTB{N{m=
ONS-76 MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vvSlEvQDd3LUK0NEBvVQ>? NEPmenE4OiCq NInzNoRFVVOR NH7lZoZKSzVyPUeuOUBvVQ>? NFLMU3kzOjN7MEK3PS=>
SUM 149 M3jjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnTUmRnOC1zMECgcm0> M2Phb|czKGh? NFLYeppqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> MlnxNlI{ODl7M{m=
MDA-MB-231 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\HcocxNTFyMDDuUS=> MUW3NkBp M4DLZolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=> M{XyTlIzOzB7OUO5
HR5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jwZlAuOTByIH7N NFvlZ4M4OiCq MVLpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK= M3;OXVIzOzB7OUO5
BT-474-M1 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe0foN6OC1zMECgcm0> M2rpO|czKGh? MUDpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK= NX7yW4dZOjJ|MEm5N|k>
AU565 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXTd441OC1zMECgcm0> MX:3NkBp Ml\mbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy NGDldHQzOjNyOUmzPS=>
T47D MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMVExOCCwTR?= M3nSdVczKGh? MlPLbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy MnnjNlI{ODl7M{m=
MCF7 NFvoeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofsNE0yODBibl2= MV23NkBp MXnpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK= MmrCNlI{ODl7M{m=
HCT116p53(+/+) MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLDNVAuOTByMDDuUS=> MXiyOE81QCCq NEfuWIxqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgSCjdDCyOUBvVQ>? MlXYNlIzPjJzN{G=
HCT116p53(-/-) MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTWNVAuOTByMDDuUS=> NVL5cmNHOjRxNEigbC=> MoTGbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJkh[XRiMkWgcm0> NXn4cXFtOjJ{NkKxO|E>
HeLa  M2\GV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;jZlkyOC1zMECgcm0> MnnEOFghcA>? NGf2VVNFVVOR M4LYb2lEPTB;NUKuPUBvVQ>? NID4[nAzOjB6MEKzOS=>
HeLa  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[3ZY9[OTBvMUCwJI5O NFvjUFI4OiCq M{jIOGROW09? M2D3TWlEPTB;NUCuOUBvVQ>? NEC1SJczOjB6MEKzOS=>
GBC M2DTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLNO|IhcA>? Mk\FTWM2OD1zND63PEBvVQ>? NXT5WnRMOjF7NkW3N|k>
GB-CL-1 M3L0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXe3NkBp MYrJR|UxRTVwMkKgcm0> NWDaTGdpOjF7NkW3N|k>
Mz-ChA-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXVO|IhcA>? NUK3SVhNUUN3ME2zMlMyKG6P M1nIU|IyQTZ3N{O5
TGBC1-TKB MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fOVlE1PCCq M1XJSGlEPTB;Nj63NkBvVQ>? NFjoeJQzOTl4NUezPS=>
Wittier NX;tS3lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTnO|IhcA>? MUnJR|UxRTNwMk[gcm0> M4nQT|IyQTZ3N{O5
H-1 M4DpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYq3NkBp M2HVPGlEPTB;OT61OEBvVQ>? MoHxNlE6PjV5M{m=
HuH-28 M3PaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH3UI9bPzJiaB?= M1;CeGlEPTB;MUGuNVkhdk1? MWSyNVk3PTd|OR?=
NEC M3SxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXFO|IhcA>? M2jBWGlEPTB;OT65PEBvVQ>? NXHifWhyOjF7NkW3N|k>
REB Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX5O|IhcA>? NGr1XZpKSzVyPUGzMlUyKG6P M4HQPFIyQTZ3N{O5
CC-LP-1 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmyO|IhcA>? MmrwTWM2OD13Lki0JI5O NHvRdmUzOTl4NUezPS=>
CC-SW-1 NGjYdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nVS|czKGh? NF3RVIdKSzVyPUmuOVUhdk1? NHu3ZWozOTl4NUezPS=>
EGI-1 MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLOfYg4OiCq MYnJR|UxRTFyLkeyJI5O NH\EXYMzOTl4NUezPS=>
Sk-ChA-1 M1TIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXvO|IhcA>? NHTtS3ZKSzVyPUG3MlIhdk1? NYPUbXBwOjF7NkW3N|k>
TFK-1 NXf5dGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXTUIVSPzJiaB?= M1nXbmlEPTB;MUOuOFUhdk1? M1LlPVIyQTZ3N{O5
786-O MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm0OU05OCCwTR?= MW[5OkBp Mn;hTGNt NIjIfZp{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= NITGfHIzOTZ2MkO3OC=>
A498 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInFSms2NThyIH7N NIWxcoo6PiCq MlTqTGNt MoTZd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P NUf6V3RUOjF4NEKzO|Q>
ACHN M4fHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12zTlUuQDBibl2= MmnZPVYhcA>? MXrIR4w> MVLzeZBxemW|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1? M1LNbFIyPjR{M{e0
Caki-1 M1TCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TLWlUuQDBibl2= MXW5OkBp MkftTGNt NFHDWnp{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= MonPNlE3PDJ|N{S=
SN12C MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPxfpRwPS16MDDuUS=> NWHKcoZCQTZiaB?= NFjWSoJJS2x? NGfTbJZ{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= Mn[wNlE3PDJ|N{S=
HMC-1.1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfKeGJDOS1zMECwJI5O NG\Hd4s4OiCq M1vn[4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>? MmK4NlEzPDJzOEm=
HMC-1.2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPCNU0yODByIH7N NF\zTYQ4OiCq NWLPUZN6cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n M3PjclIyOjR{MUi5
C2 NVPzZZVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrP[GdqOS1zMECwJI5O MoPSO|IhcA>? M37XSIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>? MoO5NlEzPDJzOEm=
CHP-212 NGTyNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjLNU0yOjVibl2= NVyyfm5xOjRvMUKwJIg> MlfsbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= MkT5NlEyPjl{NEK=
IMR-32 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[xMVEzPSCwTR?= NIPzSJQzPC1zMkCgbC=> MnXFbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= MljzNlEyPjl{NEK=
Kelly NFHJe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu3elA3OS1zMkWgcm0> MWKyOE0yOjBiaB?= Mn\vbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= MmjkNlEyPjl{NEK=
SH-EP MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfmNU0yOjVibl2= NIn6PZUzPC1zMkCgbC=> M4fpUYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= MkSyNlEyPjl{NEK=
SH-SY5Y MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDBNU0yOjVibl2= MoL2NlQuOTJyIHi= NYnETnk4cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=> MnzGNlEyPjl{NEK=
SK-N-AS M{nJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxMVEzPSCwTR?= MW[yOE0yOjBiaB?= MnGybY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= NUXkNHM6OjFzNkmyOFI>
SK-N-BE MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHnNU0yOjVibl2= NHLoOJozPC1zMkCgbC=> M{XDR4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= MoHyNlEyPjl{NEK=
KG1 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xM|ExNzFyMDDuUS=> NWLqWIxKPzJiaB?= NVPjeoZETE2VTx?= NELoe2dqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l NUnqXJBCOTl2NUizOVg>
U937 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxM|ExNzFyMDDuUS=> MkPlO|IhcA>? NIXnXHNFVVOR Mon3bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= M1vRTFE6PDV6M{W4
CAL62 NXezdmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjr[nhqOC5zLUGwNEBvVQ>? M{TVeFczKGh? M1fV[WROW09? NIi1U3JGSzVyPUGuOEBvVQ>? MUixPVIzOzV3Mx?=
OCUT-1 NInoVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr5emgxNjFvMUCwJI5O M{S0UlczKGh? NYHHemJZTE2VTx?= M4fveWVEPTB;Mj6zJI5O MXqxPVIzOzV3Mx?=
8505C MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknkNE4yNTFyMDDuUS=> MontO|IhcA>? M3iz[GROW09? M1uwcWVEPTB;Mz6yJI5O NFrRTJUyQTJ{M{W1Ny=>
ACT-1 NFPLUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrmcmpROC5zLUGwNEBvVQ>? NXX3PJhGPzJiaB?= MlftSG1UVw>? MofzSWM2OD13LkSgcm0> NUnyNmQ{OTl{MkO1OVM>
SW1736 NF\XW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LFeVAvOS1zMECgcm0> NGX6Tm84OiCq MWHEUXNQ MlzrSWM2OD13Lk[gcm0> NGPmb|QyQTJ{M{W1Ny=>

... Click to View More Cell Line Experimental Data
In vivo BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. [1]

Protocol

Kinase Assay:[1]
+ Expand

Plk1 in vitro kinase assay:

Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:[1]
+ Expand
  • Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc.
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 24 and 72 hours
  • Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BomTac:NMRI-Foxn1nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells
  • Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl
  • Dosages: ~50 mg/kg
  • Administration: Injection i.v. once or twice per week
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 100 mg/mL (191.69 mM)
DMSO 21 mg/mL (40.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing. 		15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 521.66
Formula

C28H39N7O3
CAS No. 755038-02-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT00412880 Completed Carcinoma Small Cell Boehringer Ingelheim January 2007 Phase 2
NCT02211833 Completed Carcinoma Non-Small-Cell Lung Boehringer Ingelheim October 2006 Phase 1
NCT00701766 Completed Leukemia Myeloid Acute Boehringer Ingelheim October 2006 Phase 2
NCT00706498 Completed Prostatic Neoplasms Boehringer Ingelheim September 2006 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?

  • Answer:

    For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

selleck catalog

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

  • Selective Plk Inhibitors

    GSK461364 : Plk1-selective, Ki=2.2 nM.

  • Plk Inhibitor in Clinical Trial

    Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).

  • Newest Plk Inhibitor

    Ro3280 New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

  • Calssic Plk Inhibitor

    Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products

  • SBE 13 HCl New

    SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • CCG-1423 New

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • Rigosertib (ON-01910)

    Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

  • HMN-214

    HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

  • GSK461364

    GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

    Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.

  • Volasertib (BI 6727)

    Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

    Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.

  • MLN0905

    MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

  • Ro3280

    RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

    Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.

  • NMS-P937 (NMS1286937)

    NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Tags: buy BI 2536 | BI 2536 supplier | purchase BI 2536 | BI 2536 cost | BI 2536 manufacturer | order BI 2536 | BI 2536 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID